An Electrochemiluminescence-Based Assay for MeCP2 Protein Variants

Area of Science:

• Biochemistry
• Molecular Biology
• Neuroscience

Background:

• Quantifying protein levels is crucial for understanding biological processes.
• Existing methods may lack the sensitivity or throughput for certain applications.
• Methyl-CpG binding protein 2 (MeCP2) plays a vital role in gene regulation and neurological function.

Purpose of the Study:

• To develop and validate a quantitative electrochemiluminescence immunoassay (ECLIA) for measuring MeCP2 protein.
• To assess the assay's performance in analyzing endogenous and recombinant MeCP2.
• To demonstrate the assay's utility in high-throughput screening applications.

Main Methods:

• Development of a novel ECLIA assay for MeCP2 quantification.
• Analysis of endogenous MeCP2 levels in mouse brain tissue.
• Measurement of TAT-MeCP2 uptake in human dermal fibroblasts.
• Evaluation of assay accuracy, reproducibility, and error rates.

Main Results:

• The developed ECLIA method accurately quantifies both endogenous and recombinant MeCP2 protein.
• The assay demonstrated high precision with low intra- and inter-assay variability.
• Successful analysis of MeCP2 levels in mouse brain tissue and cellular uptake studies was achieved.

Conclusions:

• A robust and versatile ECLIA has been established for quantifying MeCP2 protein variants.
• This method is suitable for high-throughput screening, facilitating research in neuroscience and related fields.
• The assay provides reliable measurements for diverse biological applications involving MeCP2.